医学
缬沙坦
厄贝沙坦
食品药品监督管理局
氯沙坦
代理(哲学)
血管紧张素II
药理学
替代医学
内科学
受体
血压
认识论
哲学
病理
作者
Hong-tian Li,Susan Hellerstein,Yu-bo Zhou,Jianmeng Liu,Jan Blustein
出处
期刊:JAMA
[American Medical Association]
日期:2020-01-07
卷期号:323 (1): 89-89
被引量:104
标识
DOI:10.1001/jama.2019.17595
摘要
2.FDA updates and press announcements on angiotensin ii receptor blocker (ARB) recalls (valsartan, losartan, and irbesartan).US Food and Drug Administration website.https://www.fda.gov/drugs/drug-safety-andavailability/fda-updates-and-press-announcements-angiotensin-ii-receptorblocker-arb-recalls-valsartan-losartan.Accessed August 9, 2019.3. FDA statement on the FDA's ongoing investigation into valsartan and ARB class impurities and the agency's steps to address the root causes of the safety issues.US Food and Drug Administration website.https://www.fda.gov/newsevents/press-announcements/fda-statement-fdas-
科研通智能强力驱动
Strongly Powered by AbleSci AI